ClinicalTrials.Veeva

Menu

Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.

H

Hasselt University

Status

Completed

Conditions

Diabetes Mellitus, Type 1

Treatments

Diagnostic Test: autonomic function testing

Study type

Interventional

Funder types

Other

Identifiers

NCT03481374
CVDIABMEL-1

Details and patient eligibility

About

testing of autonomic function and relationship with exercise and Qol in diabetic patients and controls

Full description

Cardiovascular autonomic neuropathy is a common (sub)clinical symptom in persons with type 1 diabetes mellitus. Subjects in this non-commercial, monocentric, interventional study undergo autonomic function tests, a maximal ergospirometry and three questionnaires about the quality of life (EQ-5D-3L), the capacity to do physical activities (IPAQ) and the experience of possible symptoms of autonomic dysfunction in daily life (SCOPA-AUT). In this way the influence of type 1 diabetes mellitus on the quality of life, the exercise capacity and the autonomic function can be studied.

The primary aim of this study investigates the potential correlations between the severity of diabetic cardiovascular autonomic neuropathy (DCAN) and both the quality of life and the exercise capacity. As a secondary aim, the influences of gender, age, number of years since diagnosis of type 1 diabetes mellitus, VO2 max predicted, maximal heart rate during exercise, minimal heart rate in rest, maximal RER (Respiratory exchange ratio) and relevant interaction terms are studied.

In total 52 test subjects with type 1 diabetes mellitus and 27 matched control subjects are selected to participate in this study.

Enrollment

79 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Type 1 diabetes mellitus (only for the group of subjects with diabetes mellitus)
  • At least two years with diagnosis of type 1 diabetes mellitus
  • Subject is in a stable condition
  • No hospitalization for any reason in the past three months
  • 18 years or older
  • Being capable of doing physical activities
  • Understand the study design and the informed consent
  • Sign the informed consent
  • No simultaneously participation to another study
  • Being capable of moving to the study center

Exclusion criteria

  • Uncontrolled hypertension, atrial fibrillation and other cardiovascular conditions

  • Severe lung disease

  • Muscle deficiency

  • Medication with influence on the autonomic nervous system:

    • Beta blockers
    • Alfa blockers
    • Antidepressants
    • Non-catecholamines
    • (anti) cholinergic medication

Trial design

Primary purpose

Screening

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

79 participants in 2 patient groups, including a placebo group

subjects with Type 1 Diabetes mellitus
Active Comparator group
Description:
Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
Treatment:
Diagnostic Test: autonomic function testing
Healthy controls
Placebo Comparator group
Description:
healthy people without known disease undergo autonomic function testing
Treatment:
Diagnostic Test: autonomic function testing

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems